| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To gain insight into the origin of HLA class I allele-lacking (HLA[-]) and GPI-anchored membrane protein-deficient (GPI[-]) cells and mechanisms underlying escape of these marker(-) hematopoietic stem cells (HSCs) in patients with acquired aplastic anemia (AA), we analyzed the lineage diversity of these marker(-) cells using flow cytometry. Our study revealed that the HLA lacking occurred in more immature hematopoietic stem cells (HSCs) than HSCs with PIGA mutations. The percentage of HLA(-) granulocytes continued to increase in patients in remission off cyclosporine (CsA), suggesting that the cytotoxic T cell (CTL) attack against HSCs persists even after AA patients achieved remission not requiring CsA. On the other hand, mechanisms other than immune attack by CTLs was suspected to be involved in the survival advantage of PIGA mutated HSCs.
|
